Share
A potential therapy developed at The University of Queensland may one day save lives by helping patients recover faster from severe trauma, extensive burns and major surgery.
UniQuest, UQ’s technology transfer company, has partnered with global biotechnology company CSL to accelerate the development of a potential treatment for the repair of blood vessels damaged by inflammation.
Dr Coulthard said the technology could benefit critically ill patients with sepsis or acute respiratory distress syndrome, as well as improve patient recovery from heart attack, stroke and organ transplant.
“It may also prevent high-risk patients from developing Systemic Inflammatory Response Syndrome (SIRS), which affects more than half of critically ill patients and contributes to significant mortality and morbidity,” Dr Coulthard said.
UniQuest partners with CSL to develop potential new therapy miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Date Time
Two QIMR Berghofer scientists awarded CSL Research Acceleration Initiative partnerships
Two QIMR Berghofer scientists will collaborate with leading global biotechnology company CSL on new immunological targets after being awarded Research Acceleration Initiative partnerships.
The head of the Immunology and Infection Laboratory, Professor Christian Engwerda, and the head of the Molecular Immunology Laboratory, Associate Professor Michelle Wykes, will each receive $500,000 over two years to conduct collaborative research projects with CSL.
As well as the funding, the partnerships also give the researchers access to CSL’s R&D experts.
CSL has awarded four partnerships nationally, with QIMR Berghofer receiving half of those.
Date Time
2020 RAI Awardees Announced
Four Australian medical researcher programs have been awarded a CSL Research Acceleration Initiative partnership, including a $500,000 AUD investment in each program over two years, to fast-track the discovery of innovative biotherapies to address unmet patient needs.
The CSL Research Acceleration Initiative establishes partnerships between CSL and global research organisations and includes funding as well as access to CSL R&D experts.
Marthe D’Ombrain, CSL’s Head of Global Research Innovation said, “Australian researchers have an excellent reputation globally for producing high quality, novel research. The CSL Research Acceleration Initiative is designed to enhance research commercialisation through partnerships in promising discovery programs.
Funding to tackle growing heart disease among children
29 Apr 2021 | 3 mins
Scientists at The University of Western Australia and Victor Chang Cardiac Research Institute have been awarded $500,000 to develop new treatments for the world’s leading cause of cardiac death among children.
The funding boost from global biotechnology company CSL will be used to further research into hypertrophic cardiomyopathy – also known as ‘big heart syndrome’ – which affects children between five and 15 years old.
“Right now, we have no way of preventing or reversing damage to the heart. All we can do is alleviate the symptoms.”
Professor Livia Hool
Professor Livia Hool, from UWA’s School of Human Sciences, said the award would help build on previous breakthrough discoveries and could prevent and even reverse the damage of the inherited disease, which causes the heart to become dangerously large.